Study design for Grail MCED test presented at ASCO

By LabPulse.com staff writers

June 7, 2022 -- Grail this week announced a presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago describing a study design for its Galleri multicancer early detection (MCED) blood test.

The NHS-Galleri study is a randomized and controlled clinical trial in the U.K. National Health Service's clinical practice setting.

It is among the largest studies for an MCED test, according to Grail, enrolling 140,000 healthy volunteers ages 50 to 77 in select regions throughout England who have not had a cancer diagnosis or undergone treatment for cancer in the last three years.

The study design was described in a poster presentation at ASCO by Dr. Charles Swanton, MD, PhD, a cancer researcher and oncologist at University College London.

The Galleri test detects abnormalities in the methylation patterns of cell-free DNA (cfDNA) that could indicate the presence of cancer.

Grail, AstraZeneca to collaborate on companion diagnostic tests
Grail on Thursday announced its strategic collaboration with AstraZeneca to develop and commercialize companion diagnostic (CDx) assays for use with AstraZeneca’s...
Grail collaborates with VA on Galleri study
Grail is collaborating with the U.S. Department of Veterans Affairs (VA) Health Administration on a large-scale observational study assessing the performance...
Intermountain Healthcare to offer Galleri cancer blood test
Utah-based health system Intermountain Healthcare will be offering Grail’s Galleri multicancer early detection blood test as a complement to existing...
Grail to partner with Premier
Grail has signed a collaborative agreement with Premier to use that company's PINC AI technology and services platform to expand patient access to Grail's...
Illumina completes Grail deal, despite lack of European approval
Illumina has completed its acquisition of cancer diagnostics developer Grail, almost a year after announcing the deal. Illumina said it would run Grail...

Copyright © 2022 LabPulse.com

Last Updated mp 6/7/2022 1:54:50 PM